Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

The endorsement comes as Moderna's updated Spikevax COVID-19 vaccine formulation, targeting the JN.1 variant, received approval from the Taiwan Food & Drug Administration. This follows recent ...

The endorsement comes as Moderna's updated Spikevax COVID-19 vaccine formulation, targeting the JN.1 variant, received approval from the Taiwan Food & Drug Administration. This follows recent ...

For the first time in the U.K., the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program. The updated ...

Moderna (NASDAQ:MRNA) has secured regulatory approval in the U.K. and Taiwan for an updated formulation of its COVID-19 mRNA vaccine, Spikevax. U.K. drug regulator, the Medicines and Healthcare ...

"The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 ...

Moderna’s Spikevax and Pfizer’s Comirnaty are available at GIANT and MARTIN’S pharmacies — inventory may vary by location. Vaccines for those 12 years and older are readily available. Vaccines for ...

has approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1., for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ...